AI drugmaker Anew Labs raises $290M in first independent round

The presence of established Chinese pharma groups as strategic investors, rather than purely financial backers, is the detail that separates this from a typical AI-biotech raise. It suggests the capital is tied to pipeline access, manufacturing or distribution rather than a pure software bet on drug discovery. The open question is whether that strategic participation translates into clinical or commercial milestones, or remains a financial position.